| Income Statement | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Revenues, net | 1,247 | 1,431 | 3,146 | 2,474 |
| Cost of revenues | 513 | 905 | 3,311 | 2,950 |
| Gross profit (loss) | 734 | 526 | -165 | -476 |
| Research and development | 4 | 97 | 122 | 139 |
| General and administration | 4,624 | 4,092 | 7,650 | 7,212 |
| Total operating expenses | 4,628 | 4,189 | 7,772 | 7,351 |
| Loss from operations | -3,894 | -3,663 | -7,937 | -7,827 |
| Other expense | 0 | -45 | - | 30 |
| Interest expense | 587 | 539 | 1,158 | 643 |
| Debt extinguishment loss | -287 | -431 | - | - |
| Change in fair value of warrant liability | 40 | - | - | - |
| Loss from disposal of fixed assets | -823 | - | - | - |
| Employee retention tax credit income | 1,938 | - | - | - |
| Loss from operations before income taxes | -3,693 | -4,678 | -9,095 | -8,440 |
| Income tax (expense) benefit | 779 | - | -2,508 | -2,287 |
| Loss from continuing operations after income taxes | -4,472 | -4,678 | - | - |
| Loss from discontinued operations, net of tax | 0 | -102 | - | - |
| Gain from disposal of discontinued operations | 0 | 8,746 | - | - |
| Loss from operations after income taxes | - | - | -6,587 | -6,153 |
| Income (loss) from discontinued operations | 0 | 8,644 | - | - |
| Net income (loss) | -4,472 | 3,966 | -6,587 | -6,153 |
| Unrealized gain on marketable securities | 2 | - | 1 | -58 |
| Total comprehensive loss | -4,470 | 3,966 | -6,586 | -6,211 |
| Basic (in shares) | 41,541,000 | 35,233,000 | 19,079,000 | 18,888,000 |
| Diluted (in shares) | 41,541,000 | 35,233,000 | 19,079,000 | 18,888,000 |
| Net loss per share, basic (in dollars per share) | -0.11 | 0.11 | -0.35 | -0.33 |
| Net loss per share, diluted (in dollars per share) | -0.11 | 0.11 | -0.35 | -0.33 |
ProPhase Labs, Inc. (PRPH)
ProPhase Labs, Inc. (PRPH)